tiprankstipranks
Trending News
More News >
Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
US Market
Advertisement

Sionna Therapeutics, Inc. (SION) Price & Analysis

Compare
7 Followers

SION Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Clinical TrialsInterim data from Phase 1 development for NBD1 stabilizers '719 and '451 is promising, with complete dosing and full data expected soon.
Innovative PipelineSION's pipeline of CF therapies directly target NBD1, critical to the cystic fibrosis disease process but previously thought to be undruggable.
Bears Say
Financial PerformanceSION reported a net loss of $16.5M for 1Q25.
Market CompetitionThe bear case centers around Vertex’s dominance of the CF market, raising questions about SION's ability to realistically compete.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

53.96%1.74%2.21%40.76%
53.96% Insiders
1.74%
Mutual Funds
2.21% Other Institutional Investors
40.76% Public Companies and
Individual Investors

SION FAQ

What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $25.19 in the past 12 months.
    What is Sionna Therapeutics, Inc.’s market cap?
    Sionna Therapeutics, Inc.’s market cap is $817.63M.
      When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Sionna Therapeutics, Inc.’s earnings last quarter?
      Currently, no data Available
      Is Sionna Therapeutics, Inc. overvalued?
      According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Sionna Therapeutics, Inc. pay dividends?
        Sionna Therapeutics, Inc. does not currently pay dividends.
        What is Sionna Therapeutics, Inc.’s EPS estimate?
        Sionna Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Sionna Therapeutics, Inc. have?
        Sionna Therapeutics, Inc. has 44,124,393 shares outstanding.
          What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
          Currently, no hedge funds are holding shares in SION

          Sionna Therapeutics, Inc. Stock Smart Score

          6
          Neutral
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Fundamentals

          Return on Equity
          Trailing 12-Months
          Asset Growth
          257.59%
          Trailing 12-Months

          Company Description

          Sionna Therapeutics, Inc.

          Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

          SION Stock 12 Month Forecast

          Average Price Target

          $38.50
          ▲(198.45%Upside)
          {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","46":"$46","18.25":"$18.25","27.5":"$27.5","36.75":"$36.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,18.25,27.5,36.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.9,15.36923076923077,17.838461538461537,20.307692307692307,22.776923076923076,25.246153846153845,27.715384615384615,30.184615384615384,32.65384615384615,35.12307692307692,37.59230769230769,40.06153846153846,42.53076923076923,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.9,14.86923076923077,16.838461538461537,18.807692307692307,20.776923076923076,22.746153846153845,24.715384615384615,26.684615384615384,28.653846153846153,30.623076923076923,32.59230769230769,34.56153846153846,36.53076923076923,{"y":38.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.9,14.36923076923077,15.838461538461539,17.307692307692307,18.776923076923076,20.246153846153845,21.715384615384615,23.184615384615384,24.653846153846153,26.123076923076923,27.592307692307692,29.06153846153846,30.53076923076923,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.24,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
          Similar Stocks
          Company
          Price & Change
          Follow
          Akebia Therapeutics
          SAGE Therapeutics
          Urogen Pharma
          Savara
          Maze Therapeutics, Inc.
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis